ExeVir Bio
Develops single-domain antibody-based therapies that help patients ward off viral infections.
Launch date
Employees
Market cap
-
Enterprise valuation
€123m (Public information from Mar 2021)
Company register number 0750.495.334
Ghent East Flanders (HQ)
Financials
Estimates*
| EUR | 2021 | 2022 | 2023 |
|---|---|---|---|
| Profit | (27.3m) | (1.7m) | (5.3m) |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
* | $27.0m | Series A | |
* | $23.0m Valuation: $135m | Series A | |
* | €25.0m | Debt | |
* | €1.6m | Grant | |
| Total Funding | €47.1m | ||
Recent News about ExeVir Bio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.